EP2641624A1 - Lieferung einer Behandlungslösung in eine extrakorporale Blutbehandlungsvorrichtung - Google Patents
Lieferung einer Behandlungslösung in eine extrakorporale Blutbehandlungsvorrichtung Download PDFInfo
- Publication number
- EP2641624A1 EP2641624A1 EP12001975.7A EP12001975A EP2641624A1 EP 2641624 A1 EP2641624 A1 EP 2641624A1 EP 12001975 A EP12001975 A EP 12001975A EP 2641624 A1 EP2641624 A1 EP 2641624A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment solution
- intermediate container
- controller
- source
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 464
- 239000008280 blood Substances 0.000 title claims abstract description 137
- 210000004369 blood Anatomy 0.000 title claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 8
- 238000005086 pumping Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 282
- 239000012530 fluid Substances 0.000 description 57
- 239000007788 liquid Substances 0.000 description 14
- 238000004891 communication Methods 0.000 description 8
- 230000005484 gravity Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000002615 hemofiltration Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1613—Profiling or modelling of patient or predicted treatment evolution or outcome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A61M1/1643—Constructional aspects thereof with weighing of fresh and used dialysis fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3393—Masses, volumes, levels of fluids in reservoirs, flow rates by weighing the reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3396—Reservoirs being alternately filled and emptied for measuring flow rate or delivered volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
Definitions
- Extracorporeal blood treatment means taking the blood from a patient, treating the blood outside the patient, and returning the treated blood to the patient.
- Extracorporeal blood treatment is typically used to extract undesirable matter or molecules from the patient's blood, and/or to add beneficial matter or molecules to the blood.
- Extracorporeal blood treatment is used with patients incapable of effectively eliminating matter from their blood, for example in the case of a patient who is suffering from temporary or permanent kidney failure. These and other patients may undergo extracorporeal blood treatment to add to or to eliminate matter from their blood, to maintain an acid-base balance or to eliminate excess body fluids, for instance.
- Extracorporeal blood treatment is typically performed by sampling the patient's blood in a continuous flow, by introducing the blood into a primary chamber of a filter that is defined, at least in part, by a semi-permeable membrane.
- the semi-permeable membrane may selectively allow the unwanted matter contained in the blood pass through the membrane, from the primary chamber to the secondary chamber, and may selectively allow the beneficial matter contained in the liquid going into the secondary chamber pass through the membrane to the blood going into the primary chamber, according to the type of treatment.
- a number of extracorporeal blood treatments may be performed by the same machine.
- UF ultrafiltration
- the unwanted matter is eliminated from the blood by convection through the membrane in the secondary chamber.
- HF hemofiltration
- the blood runs through a chamber that is defined, at least in part, by a semi-permeable membrane as in UF, and the beneficial matter is added to the blood, typically by the introduction of a fluid into the blood, either before, or after its passage through the filter and before it is returned to the patient.
- a secondary fluid containing the beneficial matter is introduced into the filter's secondary chamber.
- the blood's unwanted matter crosses the semi-permeable membrane by diffusion and penetrates into the secondary fluid, and the beneficial matter of the secondary fluid can cross the membrane and penetrate into the blood.
- HDF hemodiafiltration
- the secondary fluid goes through the filter's secondary chamber and receives the blood's unwanted matter by diffusion and/or convection through the membrane. This liquid is then extracted from the filter: it is commonly called effluent, and is sent to a drain or to a receptacle then intended to be discharged into a drain.
- the secondary fluid may be supplied in a sterile single-use bag as illustrated in FIG. 1 .
- the secondary fluid may be dialysate contained in a dialysate bag 11.
- the dialysate bag 11 delivers dialysate to the secondary chamber 4 through an exit line 9.
- This bag 11 is combined with a gravimetric scale 21 linked to a control unit 41.
- weight signals are transmitted to the control unit 41 that is capable of monitoring the weight changes of the bag 11 and to control a pump 31 acting on the exit line 9 (i.e., the line delivering dialysate from the bag 11 to the secondary chamber 4).
- a session can last several days and the single-use dialysate bag 11 is emptied well before the end of the session. This phenomenon is all the more pronounced during an intensive treatment. Indeed, one wishes both to exchange a large quantity of liquid in HF or HDF therapy, and to perform long-term treatments.
- the pump acting on the exit line 9 may be temporarily stopped, while the blood continues to circulate extracorporeally in the filter's primary chamber 3.
- the user has to disconnect and unhook the empty dialysate bag 11. Then the user attaches and connects a new full single-use bag 11 to the treatment apparatus and restarts the pump(s) to return to the extracorporeal treatment with fluid circulation through the two chambers (3, 4) of the filter 2.
- This bag replacement operation has several potential disadvantages.
- the operation is performed by health care personnel who have to monitor several patients at the same time (a waiting time before action by the personnel typically increases therapy down time and may require additional treatment time or result in decreased treatment efficiency), the regular changing of the dialysate bag during a session adds an economic cost to the treatment, and the bags are heavy and relatively fragile objects to handle and can potentially be perforated while handling.
- treatment solutions may include, e.g., dialysate; a replacement fluid of a convective replacement therapy of the renal function; plasma, albumin or colloid solutions that may be used in Therapeutic Plasma Exchange (TPE); or any other known type of medical fluid for replacement therapy.
- the blood treatment apparatus described herein include two or more intermediate containers that are located between a treatment solution source and a port through which the treatment solution is to be delivered with the blood treatment apparatus.
- the weight of the intermediate containers is measured and used to control the refilling and emptying of treatment solution in the intermediate containers.
- the use of two or more intermediate containers as described herein at a location between the treatment solution source and the remainder of the blood treatment apparatus may reduce or eliminate the need to halt delivery of the treatment solution to change the intermediate containers as they are emptied and/or refilled. As a result, significant increases in uninterrupted treatment duration may be possible.
- the amount of treatment solution delivered to the selected portion of the blood treatment apparatus is typically controlled based on the weight of the treatment solution delivered to the output controller as determined by the gravimetric scales described herein.
- the flow rate of the treatment solution through the output controller may also be controlled, at least in part, based on the weight changes of the intermediate containers.
- some embodiments of the blood treatment apparatus described herein include: a blood circuit that includes an arterial line intended to draw blood from a patient and a venous line intended to return blood to the patient; and a treatment solution delivery system configured to deliver treatment solution within the blood treatment apparatus through a treatment solution port.
- the treatment solution delivery system may include: a first gravimetric scale configured to weigh a first intermediate container; a second gravimetric scale configured to weigh a second intermediate container; a source flow controller configured to deliver treatment solution from a treatment solution source to a first intermediate container weighed by the first gravimetric scale and to a second intermediate container weighed by the second gravimetric scale; an output controller configured to control the flow of treatment solution from the first intermediate container and the second intermediate container to the treatment solution port; a container selection controller located in a treatment solution path between the source flow controller and the output controller; a control unit operably attached to the first gravimetric scale, the second gravimetric scale, the source flow controller, the container selection controller, and the output controller.
- the control unit is configured to: receive weight signals from the first and second gravimetric scales; control the source flow controller, the container selection controller, and the output controller in a first mode in which treatment solution is delivered to the output controller while treatment solution leaves the first intermediate container and the second intermediate container fills with treatment solution; control the source flow controller, the container selection controller, and the output controller in a second mode in which the second intermediate container delivers treatment solution to the output controller while the first intermediate container fills with treatment solution from the treatment solution source.
- control unit is configured to control the source flow controller, the container selection controller, and the output controller such that a continuous flow of treatment solution is provided to the treatment solution port when switching between the first mode and the second mode.
- the blood treatment apparatus comprises a filter having a primary chamber and a secondary chamber separated by a semi-permeable membrane, wherein the blood circuit is configured to pass blood through the primary chamber, and wherein the treatment solution port is configured to deliver treatment solution to the secondary chamber.
- the treatment solution port is configured to deliver treatment solution to blood in the blood circuit.
- the apparatus includes an air detector located between the treatment solution source and the first and second intermediate containers such that treatment solution delivered to the first intermediate container and the second intermediate container from the treatment solution source passes through the air detector.
- the apparatus comprises a sterilizing filter located between the treatment solution source and the treatment solution port such that treatment solution delivered to the treatment solution port from the treatment solution source passes through the sterilizing filter.
- a sterilizing filter is located between the treatment solution source and the first and second intermediate containers such that treatment solution delivered to the first intermediate container and the second intermediate container from the treatment solution source passes through the sterilizing filter.
- the apparatus includes a source flow controller located between the treatment solution source and the first and second intermediate containers such that treatment solution delivered to the first intermediate container and the second intermediate container from the treatment solution source passes through the source flow controller.
- a sterilizing filter may be located between the source flow controller and the first and second intermediate containers such that treatment solution delivered to the first intermediate container and the second intermediate container from the treatment solution source passes through the sterilizing filter.
- the sterilizing filter (if included) may have a passive air vent that comprises a hydrophobic membrane.
- the treatment solution source comprises a plurality of supply reservoirs.
- the treatment solution source comprises a liquid source, treatment solution precursor, and mixing apparatus configured to combine liquid from the liquid source and the treatment solution precursor to form the treatment solution.
- the container selection controller comprises a valve configured to have an open state in which flow through a line on which the valve acts is allowed and a closed state in which flow through a line on which the valve acts is prevented.
- the container selection controller comprises a pump configured to deliver treatment solution through a line on which the pump is located when the pump is operating and to prevent flow of treatment solution through the line on which the pump is located when the pump is not operating.
- the container selection controller comprises a multi-port valve, wherein in a first configuration the multi-port valve allows treatment solution from the treatment solution source to flow into the first intermediate container and prevent the treatment solution from flowing into the second intermediate container, and wherein in a second configuration the multi-port valve allows treatment solution from the treatment solution source to flow into the second intermediate container and prevent the treatment solution from flowing into the first intermediate container.
- the first intermediate container outlet flow controller and the second intermediate container outlet flow controller comprise a multi-port valve, wherein in a first configuration the multi-port valve allows treatment solution from the first intermediate container to flow to the output controller and prevent flow of treatment solution from the second intermediate container to the output controller, and wherein in a second configuration the multi-port valve allows treatment solution from the second intermediate container to flow to the output controller and prevent flow of treatment solution from the first intermediate container to the output controller.
- control unit is configured to calculate, from the received weight signals, the amount of treatment solution delivered to the output controller from both the first intermediate container and the second intermediate container.
- some embodiments of the methods of controlling treatment solution flow in a blood treatment apparatus may include: filling a first intermediate container with treatment solution by delivering treatment solution from a treatment solution source to the first intermediate container, weighing the first intermediate container to determine when the amount of treatment solution in the first intermediate container has risen to a selected fill level, and halting the delivery of treatment solution to the first intermediate container when the amount of treatment solution in the first intermediate container has risen to the selected fill level; and delivering treatment solution from a second intermediate container to an output controller while filling the first intermediate container from the treatment solution source, weighing the second intermediate container to determine when the amount of treatment solution in the second intermediate container has fallen to a selected refill level, and halting the delivery of treatment solution to the output controller when the amount of treatment solution in the second intermediate container has fallen to the selected refill level.
- the blood treatment apparatus used to practice some embodiments of the methods described herein may be any of the various embodiments of blood treatment apparatus described herein.
- the methods described may include filling the second intermediate container with treatment solution by delivering treatment solution from the treatment solution source to the second intermediate container, weighing the second intermediate container to determine when the amount of treatment solution in the second intermediate container has risen to a selected fill level, and halting the delivery of treatment solution to the second intermediate container when the amount of treatment solution in the second intermediate container has risen to the selected fill level; and delivering treatment solution from the first intermediate container to the output controller while filling the second intermediate container from the treatment solution source, weighing the first intermediate container to determine when the amount of treatment solution in the first intermediate container has fallen to a selected refill level, and halting the delivery of treatment solution to the output controller when the amount of treatment solution in the first intermediate container has fallen to the selected refill level.
- the methods described herein may include replacing one or more supply reservoirs of a plurality of supply reservoirs in the treatment solution source while delivering treatment solution to the first intermediate container or the second intermediate container.
- the methods described herein may include constituting treatment solution from a treatment solution precursor and a liquid source in the treatment solution source while delivering treatment solution to the first intermediate container or the second intermediate container.
- the treatment solution is delivered substantially continuously to the output controller.
- the methods described herein may include passing the treatment solution from the treatment solution source through an air detector when delivering treatment solution from the treatment solution source to the first intermediate container or the second intermediate container.
- the methods described herein may include passing the treatment solution from the treatment solution source through a sterilizing filter when delivering treatment solution from the treatment solution source to the first intermediate container or the second intermediate container.
- filling the first intermediate container or the second intermediate container comprises pumping treatment solution from the treatment solution source through a source flow controller to the first intermediate container or the second intermediate container.
- the amount of treatment solution delivered to the output controller from both the first intermediate container and the second intermediate container is calculated based on weight of the first and second intermediate containers.
- a blood treatment apparatus 1 is depicted.
- the depicted blood treatment device 1 is in an operational configuration that enables it to perform a hemodialysis treatment.
- the other treatment configurations mentioned previously are of course possible within other embodiments, and the principles, systems, and methods described herein may be applied in those embodiments as well..
- the blood treatment apparatus 1 depicted in FIGS. 2 , 5 , and 8 includes a filter 2 having a primary chamber 3 and a secondary chamber 4 separated by a semi-permeable membrane 5.
- a blood circuit in the blood treatment apparatus 1 includes an arterial line 7 intended to draw blood from the patient, the filter's primary chamber 3 and a venous line 6 intended to return blood to the patient from the primary chamber 3.
- Treatment solution (e.g., dialysate, etc.) is delivered to the blood treatment apparatus 1 in each embodiment. Because the treatment solution in each of the depicted embodiments is dialysate, the treatment solution is delivered to the secondary chamber 4 of the filter 2 through a treatment solution port 10 connected to inlet line 9 using output controller 31. Liquids are removed from the secondary chamber 4 of the filter 2 through a drain line 8.
- the output controller 31 is, in the embodiments of FIGS. 2 , 5 , and 8 depicted in the form of a peristaltic pump, the output controller 31 may be provided in a variety of alternative forms that can be used to control the flow of the treatment solution including, e.g., other pumps (e.g., piston pumps, diaphragm pumps, etc.), other flow control mechanisms (e.g., valves, clamps, etc.), etc.
- other pumps e.g., piston pumps, diaphragm pumps, etc.
- other flow control mechanisms e.g., valves, clamps, etc.
- each embodiment of the blood treatment apparatus depicted in FIGS. 2 , 5 , and 8 involves delivery of treatment solution (in the form of, e.g., dialysate) to the secondary chamber 4 of the filter 2 through treatment solution port 10 connected to inlet line 9, other treatment solutions may, in other embodiments, be delivered directly to blood in the arterial line 7 and/or venous line 6 (or even, in some embodiments, into the blood resident in primary chamber 3).
- treatment solution in the form of, e.g., dialysate
- the blood treatment apparatus as described herein may include the delivery of two or more different treatment solutions to the same or different locations within the blood treatment apparatus.
- treatment solution in the form of dialysate may be delivered to the secondary chamber 4 of the filter as depicted in the embodiments of FIGS. 2 , 5 , and 8 while one or more different treatment solutions are delivered to, e.g., the blood in primary chamber 3, arterial line 7, and/or venous line 6.
- the treatment solution delivered by the treatment solution delivery system within the blood treatment apparatus described herein is supplied using two or more intermediate containers.
- the weight of the intermediate containers can be measured and may be used to control the refilling and emptying of treatment solution in the intermediate containers.
- the amount of treatment solution delivered to the selected portion of the blood treatment apparatus can also be controlled, at least in part, based on the weight and/or weight changes of the intermediate containers.
- the treatment solution in the two or more intermediate containers is provided to the intermediate containers from a treatment solution source which may potentially reduce or eliminate the need to halt delivery of the treatment solution to change the intermediate containers as they are emptied and/or refilled.
- the "intermediate containers” may take any suitable form in which liquids can be stored, e.g., bags, bottles, reservoirs, etc.
- a first intermediate container 11 and a second intermediate container 12 are used to supply treatment solution to the output controller 31 that, in turn, supplies treatment solution to the treatment solution port 10 that, in the depicted embodiment, is connected to inlet line 9.
- a first gravimetric scale 21 is configured to weigh the first intermediate container 11, with the weight being indicative of the amount of treatment solution contained in the first intermediate container 11.
- a second gravimetric scale 22 is configured to weigh the second intermediate container 12, with the weight being indicative of the amount of treatment solution contained in the second intermediate container 12.
- control unit 41 is linked to the first gravimetric scale 21 and the second gravimetric scale 22, as well as the output controller 31.
- the control unit 41 may be linked to the various fluid flow control components (in addition to the first gravimetric scale 21, the second gravimetric scale 22, and the output controller 31) such that one of the intermediate containers (11, 12) is filled with treatment solution while treatment solution exits from the other intermediate container (12, 11), and vice-versa.
- the control unit 41 may be provided in any suitable form and may, for example, include memory and a controller.
- the controller may, for example, be in the form of one or more microprocessors, Application Specific Integrated Circuit (ASIC) state machines, etc.
- the control units 41 may include a variety of any suitable input devices configured to allow a user to operate the apparatus (e.g., keyboards, touchscreens, mice, trackballs, etc.), as well as display devices configured to convey information to a user (e.g., monitors (which may or may not be touchscreens), indicator lights, etc.).
- the blood treatment apparatus described herein include an output controller 31 acting downstream from the first intermediate container 11 and the second intermediate container 12.
- the control unit 41 may be configured to control the output controller 31 to provide substantially continuous flow of the treatment solution to the treatment solution port 10 during the treatment delivered using the blood treatment apparatus.
- the various fluid flow control components and reservoirs found in the apparatus are controlled to provide substantially continuous flow of treatment solution through the treatment solution port 10 (at a constant flow rate and/or at a variable flow rate according to a selected flow rate profile).
- the weight information supplied to the control unit 41 by the first gravimetric scale 21 is used to monitor the weight of the first intermediate container 11 so as both to know the amount of treatment solution flowing out of the first intermediate container 11, and to control the loading and unloading phase of the first and second intermediate containers 11, 12 by using two preselected threshold values (e.g., 11.1 and 11.2) that can be set based on the volume of each intermediate container.
- two preselected threshold values e.g., 11.1 and 11.2
- the second gravimetric scale 22 provides weight information to the control unit 41 so that the weight of the second intermediate container 12 can be monitored. That weight information can be used to determine the amount of treatment solution flowing out of the second intermediate container 12. That weight information can also be used to control the cyclic loading and unloading process by using one or two threshold values (e.g., 12.1 and 12.2) for the second gravimetric scale together with one or two threshold values (11.1 and 11.2) for the first gravimetric scale. If the use of two threshold values is enough for control of treatment solution flow control, the four threshold values of the two gravimetric scales can, in some embodiments, be used for other functions such as, e.g., preventive alarm purposes concerning an abnormal state for a bag, etc.
- one or two threshold values e.g., 12.1 and 12.2
- the four threshold values of the two gravimetric scales can, in some embodiments, be used for other functions such as, e.g., preventive alarm purposes concerning an abnormal state for a bag, etc.
- control unit 41 is configured to calculate the amount of treatment solution delivered to blood treatment apparatus from the treatment solution source 60 based on the weight signals received from gravimetric scales that are configured to weigh each of the intermediate containers used to deliver fluid to the output controller 31 (which, in the depicted embodiments includes first and second gravimetric scales (21 and 22), but could include more gravimetric scales if more than two intermediate containers are used to feed the output controller 31).
- Each of the illustrative embodiments of the blood treatment apparatus depicted in FIGS. 2 , 5 , and 8 includes a treatment solution source 60 that provides treatment solution to the intermediate containers that are, in turn, used to supply treatment solution to the output controller 31.
- the treatment solution source 60 is in fluid communication with a container selection controller 32 that can be used to direct treatment solution from the treatment solution source 60 to the first intermediate container 11 or the second intermediate container depending on which intermediate container needs to be refilled.
- the treatment solution source 60 supplies treatment solution to the container selection controller 32 through a source flow controller 33.
- the source flow controller 33 is, in the embodiments of FIGS. 2 , 5 , and 8 depicted in the form of a peristaltic pump, the source flow controller 33 may be provided in a variety of alternative forms that can be used to control the flow of the treatment solution including, e.g., other pumps (e.g., piston pumps, diaphragm pumps, etc.), other flow control mechanisms (e.g., valves, clamps, etc.), etc.
- other pumps e.g., piston pumps, diaphragm pumps, etc.
- other flow control mechanisms e.g., valves, clamps, etc.
- the treatment solution in the treatment solution source 60 may, in the embodiment depicted in FIG. 2 , include a plurality of reservoirs 61, 62, 63 that can be independently replaced to ensure that the treatment solution source 60 can continue to provide treatment solution to the container selection controller 32.
- the reservoirs 61, 62, 63 can take any form suitable for containing a delivering a liquid such as, e.g., bags, bottles, etc.
- the reservoirs 61, 62, 63 may be adapted for a single use (after which they would be disposed of), but the reservoirs 61, 62, 63 could be refillable when they are not connected within the treatment solution source 60 to deliver treatment solution.
- all of the reservoirs 61, 62, 63 may be in fluid communication with the source flow controller 33 at the same time, while in other embodiments, it may be possible to selectively place one or more of the reservoirs 61, 62, 63 in fluid communication with the source flow controller 33 while one or more of the reservoirs 61, 62, 63 are not in fluid communication with the source flow controller 33 (they may be, e.g., disconnected, or have a fluid line that is closed by a valve, clamp, or other flow controller).
- the treatment solution source 60 depicted in FIG. 2 includes three reservoirs 61, 62, 63, other embodiments may be operated with as few as one or two reservoirs, while still other embodiments of the treatment solution source may be provided with four or more reservoirs containing treatment solution. Also, in some embodiments, the reservoirs may all contain the same volume of liquid or they may contain different volumes of the treatment solution.
- the treatment solution source 60 includes a reservoir fill monitor 66 that is configured to monitor the fill status of the reservoirs 61, 62, 63 (either individually or collectively).
- the fill monitor 66 may monitor the fluid volumes using any suitable technique or combination of techniques, e.g., using weight, using capacitive, optical, or other sensors, using fluid pressure (in, e.g., line 44), etc.
- the fill monitor 66 may potentially be operably linked to the control unit 41 such that when a reservoir 61, 62, 63 needs to be refilled, the blood treatment apparatus 1 can provide an alert or indicator (e.g., visible, audible, etc.) so that appropriate action can be taken.
- an alert or indicator e.g., visible, audible, etc.
- any alert or indicator may be activated when the collective amount of treatment solution in the reservoirs 61, 62, 63 reaches a selected lower limit, e.g., a limit of 1/3 of the maximum amount of treatment solution that would be contained in three reservoirs (implying that at least one of the reservoirs 61, 62, 63 may need to be replaced, refilled, etc.).
- FIGS. 2 , 5 , and 8 Another optional feature found in the embodiments of the blood treatment apparatus 1 depicted in FIGS. 2 , 5 , and 8 is an air detector 70 that may be located in the fluid delivery line 44 leading from the treatment solution source 60 to the source flow controller 33.
- the air detector 70 can be used to detect air in the line 44 before it reaches the source flow controller 33. At that time, appropriate action can be taken by an operator to replace any empty reservoirs in the treatment solution source 60 or take any other suitable action needed to address the reason for air in the line 44.
- the control unit 41 (which is operably connected to the air detector 70 and the source flow controller 33) can, in some embodiments, be configured to operate the source flow controller 33 in reverse such that treatment solution in the line 44 can refill the fluid circuit back to the treatment solution source 60.
- the intermediate containers downstream of the container selection controller 32 e.g., first and second intermediate containers 11 and 12
- the intermediate containers downstream of the container selection controller 32 should be filled from the bottom of the intermediate container such that treatment solution in the intermediate container can be withdrawn from the intermediate container through the same line used to fill the intermediate container during reverse operation of the source flow controller 33, with the withdrawn treatment solution being used in part to assist in the refilling of the fluid lines between the intermediate container (11 or 12) and the treatment solution source 60.
- the sterilizing filter 80 may be located in the fluid delivery path upstream of the container selection controller 32. In some embodiments, the sterilizing filter 80 may be located downstream from the source flow controller 33 (i.e., between the flow controller 33 and the container selection controller 32), although other locations are also possible (e.g., upstream of the flow controller 33).
- the sterilizing filter 80 is provided to reduce the likelihood of or delivering contaminated treatment solution to the container selection controller 32 for delivery to the intermediate containers used to supply the output controller 31.
- the sterilizing filter 80 may, in some embodiments, include a vent (e.g., a passive vent in the form of a hydrophobic membrane) to assist with removal of air that may be entrained within the treatment solution.
- a vent e.g., a passive vent in the form of a hydrophobic membrane
- the sterilizing filter 80 may, in some embodiments, be located downstream from the source flow controller 33. Placing the filter 80 downstream from the flow controller 33 may eliminate the development of a negative pressure within the line 44 feeding the flow controller 33 and any associated fluid degassing that could occur as a result.
- control units 41 in the illustrative embodiments of the blood treatment apparatus depicted in FIGS. 2 , 5 , and 8 may be capable of receiving weight information from the first gravimetric scale 21 and/or the second gravimetric scale 22, calculating the actual flow rate of the treatment solution delivered to the treatment solution port 10, comparing it with a selected constant flow rate or with a selected flow rate profile, and controlling the actual flow rate of the treatment solution using the fluid flow output controller 31, the source flow controller 33 and/or any other fluid flow control mechanisms (e.g., pumps, valves, clamps, etc.) that may be provided in the blood treatment apparatus described herein.
- any other fluid flow control mechanisms e.g., pumps, valves, clamps, etc.
- the control unit 41 may also be configured to receive weight information from the first gravimetric scale 21 and/or from the second gravimetric scale 22, determine the filling status of each intermediate container, and control, based on the filling status of each intermediate container, an alternating and successive intermediate container loading and unloading process during delivery of treatment solution to the treatment solution port 10.
- control unit 41 may be configured to receive weight information from the first gravimetric scale 21 and/or from the second gravimetric scale 22, detect the upper and lower threshold values for each of the intermediate containers (e.g., 11.2, 11.1, 12.2, 12.1), and control, based on the threshold values, an intermediate container loading and unloading procedure according to the following process: loading first intermediate container 11 to an upper limit threshold (e.g., 11.1) while unloading second intermediate container 12 until a lower limit threshold (e.g., 12.2) is detected for the second intermediate container 12, followed by unloading the first intermediate container 11 until its lower limit threshold (e.g., 11.2) is detected while loading the second intermediate container 12 to its upper limit threshold (e.g., 12.1).
- an upper limit threshold e.g. 11.1
- a lower limit threshold e.g., 12.2
- the rate of fluid flow from the source flow controller 33 should be greater than the rate at which the first intermediate container 11 and the second intermediate container 12 are unloaded (which corresponds to the flow rate of treatment solution being delivered through port 10 by the output controller 31). Maintaining that flow rate relationship should typically ensure that the intermediate container that is being loaded reaches its upper limit threshold before the intermediate container that is being unloaded reaches its lower limit threshold. If, in some embodiments, the flow rate of treatment solution delivered through the source flow controller 33 is less than the flow rate from the output controller 31 to the port 10, then flow through the port 10 will typically need to be halted occasionally to allow for refilling of the intermediate containers.
- the apparatus 1 includes the components related to the delivery of treatment solution in the blood treatment apparatus 1 that are common to the different embodiments described herein. Those common components include the first intermediate container 11, second intermediate container 12, first gravimetric scale 21, second gravimetric scale 22, output controller 31, container selection controller 32, source flow controller 33, control unit 41, treatment solution source 60, air detector 70, and sterilizing filter 80.
- the container selection controller 32 includes an outlet port 51 and an inlet port 52. Treatment solution flows into the container selection controller 32 from the treatment solution source 60 (through source flow controller 33) through the inlet port 52. Treatment solution flows out of the container selection controller 32 through the outlet port 51 where it flows into the output controller 31.
- the various components within the container selection controller 32 allow for the selective loading and unloading of the first intermediate container 11 and the second intermediate container 12 while also providing the ability to maintain a substantially continuous flow of treatment solution to the output controller 31 through the outlet port 51.
- first line 57 connects the outlet port 51 with each of the two output ports (53 and 55) of the first and second intermediate containers (11 and 12).
- Flow controllers (122 and 124) are provided to act on the first line 57 between the output ports (53 and 55) and the outlet port 51 to either allow or prevent flow through the first line 57 to the outlet port 51.
- the flow controllers (122 and 124) may be in the form of, e.g., valves, clamps, pumps, etc.
- the container selection controller 32 depicted in FIG. 2 also includes a second line 58 that places the inlet port 52 into fluid communication with each of the two input ports (54 and 56) of the first and second intermediate containers (11 and 12).
- Flow controllers (121 and 123) are provided to act on the second line 58 between the inlet port 52 and the input ports (54 and 56) to either allow or prevent flow of treatment solution through the second line 58 to the input ports (54 and 56).
- the flow controllers (121 and 123) may be in the form of, e.g., valves, clamps, pumps, etc.
- the first intermediate container 11 and the second intermediate container 12 are alternately loaded and unloaded by controlling the various flow controllers (121, 122, 13, 124) in the container selection controller 32 so that a substantially continuous flow of treatment solution can be provided to the outlet port 51 which feeds the output controller 31.
- FIGS. 3 and 4 depict operation of the blood treatment apparatus 1 such that the intermediate containers (11 and 12) can be alternately loaded and unloaded through the first and second lines (57 and 58).
- the flow controller 121 is open and flow controller 123 is closed.
- treatment solution can flow into the first intermediate container 11 from the source flow controller 33 through second line 58, but is prevented from flowing into the second intermediate container 12 by the closed flow controller 123.
- Flow controller 122 on first line 57 is closed and flow controller 124 is open in the configuration depicted in FIG. 3 .
- treatment solution can flow from the second intermediate container 12 to the output controller 31 through first line 57, but is prevented from flowing out of the first intermediate container 11 by the closed flow controller 122.
- the configuration depicted in FIG. 3 can, therefore, be described as a configuration in which the first intermediate container 11 is filled or loaded through second line 58 while the second intermediate container 12 is emptying or unloading through first line 57.
- FIG. 4 depicts a different configuration for the blood treatment apparatus 1 of FIG. 2 in which the first intermediate container 11 is emptying or unloading while the second intermediate container 12 is filled or loaded.
- the flow controller 123 is open and flow controller 121 is closed.
- treatment solution can flow into the second intermediate container 12 from the source flow controller 33 through second line 58, but is prevented from flowing into the first intermediate container 11 by the closed flow controller 121.
- Flow controller 124 is also closed and flow controller 122 is open in the configuration depicted in FIG. 4 .
- treatment solution can flow from the first intermediate container 11 to the output controller 31 through first line 57, but is prevented from flowing out of the second intermediate container 12 by the closed flow controller 124.
- control unit 41 may be configured to control the container selection controller 32 such that changeovers between the configurations depicted in FIGS. 3 and 4 be accomplished in a manner that provides for continuous flow of treatment solution to the output controller 31 and, thus, the port 10.
- both flow controllers 122 and 124 on first line 57 be open at the same time before one of the flow controllers is closed when switching between the configurations depicted in FIGS. 3 and 4 .
- a brief interruption e.g., 60 seconds or less
- a brief interruption e.g. 60 seconds or less
- substantially continuous treatment solution delivery as described herein.
- the control unit 41 may be configured to control the output controller 31 in different configurations.
- the control unit 41 controls the output controller 31, the container selection controller 32, and the source flow controller 33 to achieve a selected flow rate profile of treatment solution through the treatment solution port 10 based on weight information coming from either the first gravimetric scale 21 or the second gravimetric scale 22 when only one of the first intermediate container 11 or the second intermediate container 12 is being unloaded (while, e.g., the other intermediate container is being filled).
- the flow rate of treatment solution through the output controller 31 is a function of the rate of change in the amount of treatment solution in the first intermediate container 11 or the second intermediate container 12. Selection of the gravimetric scale (21 or 22) is based on which intermediate container (11 or 12) is being unloaded at that time.
- control unit 41 controls the output controller 31, the container selection controller 32, and the source flow controller 33 to achieve a selected flow rate profile of treatment solution through the treatment solution port 10 based on weight information coming from both the first and second gravimetric scales (21, 22).
- This configuration may be used when, e.g., the flow controllers 122 and 124 are both open such that treatment solution could be delivered to the first line 57 from both the first intermediate container 11 and the second intermediate container 12.
- the apparatus 1 includes the components related to the delivery of treatment solution in the blood treatment apparatus 1 that are common to the different illustrative embodiments described herein.
- Those common components include the first intermediate container 11, second intermediate container 12, first gravimetric scale 21, second gravimetric scale 22, output controller 31, container selection controller 32, source flow controller 33, control unit 41, treatment solution source 60, air detector 70, and sterilizing filter 80.
- the container selection controller 32 also includes an outlet port 51 and an inlet port 52. Treatment solution flows into the container selection controller 32 from the treatment solution source 60 (through source flow controller 33) through the inlet port 52. Treatment solution flows out of the container selection controller 32 through the outlet port 51 where it flows into the output controller 31.
- the various components within the container selection controller 32 allow for the selective loading and unloading of the first intermediate container 11 and the second intermediate container 12 while also providing the ability to maintain a substantially continuous flow of treatment solution to the output controller 31 through the outlet port 51.
- first line 57 connects the outlet port 51 with each of the two output ports (53 and 55) of the first and second intermediate containers (11 and 12).
- Flow controller 125 is provided to act on the first line 57 between the output ports (53 and 55) on the first and second intermediate containers (11 and 12) and the outlet port 51 to either allow or prevent flow through the first line 57 to the outlet port 51.
- the flow controller 125 may be in the form of, e.g., a multiport flow controller that is capable of being configured between at least two alternate configurations in which flow through first line 57 from one of the output ports (53 and 55) is allowed while flow through the first line 57 from the other output port is prevented.
- the multiport flow controller 125 may have a third configuration in which flow through first line 57 from both of the output ports (53 and 55) is allowed.
- the multiport flow controller 125 may be provided in the form of a multiport valve, a clamp assembly, etc.
- the multiport flow controller 125 may be operably linked to the control unit 41 as depicted in FIG. 5 such that the control unit 41 can be used to switch the multiport flow controller 125 between its various configurations.
- the container selection controller 32 depicted in FIG. 5 also includes a second line 58 that places the inlet port 52 into fluid communication with each of the two input ports (54 and 56) of the first and second intermediate containers (11 and 12).
- a flow controller 126 is provided to either allow or prevent flow of treatment solution through the second line 58.
- the flow controller 126 may be in the form of, e.g., a multiport flow controller that is capable of being configured between at least two alternate configurations in which flow through second line 58 to one of the input ports (54 and 56) is allowed while flow through the second line 58 to the other input port is prevented.
- the multiport flow controller 126 may have a third configuration in which flow through second line 58 to both of the input ports (54 and 56) is allowed.
- the multiport flow controller 126 may be provided in the form of a multiport valve, a clamp assembly, etc. In some embodiments, the multiport flow controller 126 may be operably linked to the control unit 41 as depicted in FIG. 5 such that the control unit 41 can be used to switch the multiport flow controller 126 between its various configurations.
- the first intermediate container 11 and the second intermediate container 12 are alternately loaded and unloaded by controlling the flow controllers (125 and 126) in the container selection controller 32 so that a substantially continuous flow of treatment solution can be provided to the outlet port 51 which feeds the output controller 31.
- FIGS. 6 and 7 depict operation of the blood treatment apparatus 1 such that the intermediate containers (11 and 12) can be alternately loaded and unloaded through the first and second lines (57 and 58).
- the flow controller 126 is configured to allow treatment solution to flow into the first intermediate container 11 from the source flow controller 33 through second line 58, while preventing treatment solution from flowing into the second intermediate container 12.
- Flow controller 125 is, in the embodiment depicted in FIG. 6 , configured to allow treatment solution to flow from the second intermediate container 12 to the output controller 31 through first line 57, while preventing treatment solution from flowing out of the first intermediate container 11.
- the configuration depicted in FIG. 6 can, therefore, be described as a configuration in which the first intermediate container 11 is filled or loaded through second line 58 while the second intermediate container 12 is emptying or unloading through first line 57.
- FIG. 7 depicts a different configuration for the blood treatment apparatus 1 of FIG. 5 in which the first intermediate container 11 is emptying or unloading while the second intermediate container 12 is filled or loaded.
- the flow controller 126 is configured such that treatment solution can flow into the second intermediate container 12 from the source flow controller 33 through second line 58, while treatment solution is prevented from flowing into the first intermediate container 11.
- Flow controller 125 is, in the embodiment depicted in FIG. 7 , configured to allow treatment solution to flow from the first intermediate container 11 to the output controller 31 through first line 57, while treatment solution is prevented from flowing out of the second intermediate container 12 through first line 57.
- the configuration depicted in FIG. 7 can, therefore, be described as a configuration in which the first intermediate container 11 is emptying or unloading through first line 57 while the second intermediate container 12 is loading or filling through second line 58.
- control unit 41 may be configured to control the container selection controller 32 such that changeovers between the configurations depicted in FIGS. 6 and 7 be accomplished in a manner that does not interrupt the flow of treatment solution to the output controller 31.
- the flow controller 125 may allow treatment solution from both the first intermediate container 11 and the second intermediate container 12 to flow through first line 57 to the treatment solution output flow controller 31 when switching between the configurations depicted in FIGS. 6 and 7 .
- the control unit 41 may be configured to control the output controller 31 in different configurations.
- the control unit 41 controls the output controller 31, the container selection controller 32, and the source flow controller 33 to achieve a selected flow rate profile of treatment solution through the treatment solution port 10 based on weight information coming from either the first gravimetric scale 21 or the second gravimetric scale 22 when only one of the first intermediate container 11 or the second intermediate container 12 is being unloaded (while, e.g., the other intermediate container is being filled).
- the flow rate of treatment solution through the output controller 31 is a function of the rate of change in the amount of treatment solution in the first intermediate container 11 or the second intermediate container 12. Selection of the gravimetric scale (21 or 22) is based on which intermediate container (11 or 12) is being unloaded at that time.
- control unit 41 controls the output controller 31, the container selection controller 32, and the source flow controller 33 to achieve a selected flow rate profile of treatment solution through the treatment solution port 10 based on weight information coming from both the first and second gravimetric scales (21, 22).
- This configuration may be used if, e.g., the flow controller 125 allows treatment solution to flow through the first line 57 from both the first intermediate container 11 and the second intermediate container 12.
- the treatment solution source 60 which, rather than including a plurality of reservoirs of treatment solution as described in connection with the embodiment depicted in FIG. 2 , includes a liquid source 67, treatment solution precursor 68, and mixing apparatus 69 configured to combine liquid from the liquid source 67 (e.g., water, a suitable aqueous solution, etc.) and the treatment solution precursor 68 (e.g., a concentrated solution of dialysate, etc.) to form the treatment solution.
- the treatment solution delivered using the treatment solution source 60 of FIG. 5 is not provided in reservoirs, but is, instead, constituted within the treatment solution source 60.
- the apparatus 1 includes the components related to the delivery of treatment solution in the blood treatment apparatus 1 that are common to the different illustrative embodiments described herein.
- Those common components include the first intermediate container 11, second intermediate container 12, first gravimetric scale 21, second gravimetric scale 22, output controller 31, container selection controller 32, source flow controller 33, control unit 41, treatment solution source 60, air detector 70, and sterilizing filter 80.
- gravity is used to, in part, control the loading and unloading of the first intermediate container 11 and the second intermediate container 12.
- the vertical position of the first intermediate container 11 relative to the second intermediate container 12 is used in combination with the container selection controller 32, the output controller 31 and the source flow controller 33 by the control unit to selectively load and unload the first and second intermediate containers 11 and 12.
- the source flow controller 33 is connected to the output controller 31through a fluid line 157.
- the first intermediate container 11 is in fluid communication with the fluid line 157 through fluid line 152 which connects to fluid line 157 at junction 153.
- the second intermediate container 12 is in fluid communication with fluid line 157 through fluid line 154 which connects with fluid line 157 at junction 155.
- the container selection controller 32 is, in the depicted embodiment, positioned along fluid line 157 between junctions 153 and 155.
- Gravity is used in the blood treatment apparatus one depicted in FIG. 8 by positioning the first intermediate container 11 at a higher vertical location than the second intermediate container 12.
- the upper limit (e.g., 12.1) of the second intermediate container 12 is located lower or at the same level as the lower limit (e.g., 11.2) of the first intermediate container 11.
- the first intermediate container 11 and the second intermediate container 12 are alternately loaded and unloaded by controlling the container selection controller 32 along with the source flow controller 33 so that a substantially continuous flow of treatment solution can be provided to the output controller 31.
- FIGS. 9 and 10 depict operation of the blood treatment apparatus 1 depicted in FIG. 8 such that the intermediate containers (11 and 12) can be alternately loaded and unloaded through fluid lines 152, 154 and 157.
- the container selection controller 32 is closed.
- treatment solution flows into the first intermediate container 11 from the source flow controller 33 through fluid lines 152 and 157, while treatment solution is prevented from flowing past the container selection controller 32 to either second intermediate container 12 or the output controller 31.
- treatment solution from the source flow controller 33 fills or loads the first intermediate container 11 in the configuration depicted in FIG. 9 .
- With container selection controller 32 closed in FIG. 9 the treatment solution in the second intermediate container 12 flows out of the second intermediate container 12 to the output controller 31.
- the configuration depicted in FIG. 9 can, therefore, be described as a configuration in which the first intermediate container 11 is filled or loaded while the second intermediate container 12 is emptying or unloading.
- FIG. 10 depicts a different configuration for the blood treatment apparatus 1 of FIG. 8 in which the first intermediate container 11 is emptying or unloading while the second intermediate container 12 is filled or loaded with treatment solution.
- the source flow controller 33 is stopped or closed so that no treatment solution is being delivered into the fluid line 157 through the flow controller 33 and the container selection controller 32 is open.
- the first intermediate container 11 is higher than the second intermediate container 12
- treatment solution will flow into the fluid line 157 from the first intermediate container 11 to deliver treatment solution to both the output controller 31 and the second intermediate container 12.
- the treatment solution introduced into fluid line 157 from the first intermediate container 11 in excess of that removed from fluid line 157 by the output controller 31 will flow into the second intermediate container 12.
- the configuration depicted in FIG. 10 can, therefore, be described as a configuration in which the first intermediate container 11 is emptying or unloading through fluid line 157 while the second intermediate container 12 is loading or filling.
- Two conditions that should be met for continuous flow through the output controller 31 are: 1) the source flow should be greater than the output flow, i.e., Q33 > Q31; and 2) the gravity-driven flow rate Q2g is large enough to fill the second intermediate container 12 in a timely manner while still feeding the output controller 31, i.e., Q2g > (Q31/(Q33/(Q31-1)).
- the gravity-driven flow rate of treatment solution from the first intermediate container 11 to the second intermediate container 12 should be at least half of the desired flow rate through the output controller 31 (i.e., Q2g ⁇ (Q31/2).
- the gravity-driven flow rate of treatment solution from the first intermediate container 11 to the second intermediate container 12 should be at least twice the desired flow rate through the output controller 31 (i.e., Q2g ⁇ (2xQ31)).
- FIG. 11 represents, for the embodiment of the blood treatment apparatus depicted in FIGS. 8-10 , the weight changes of the first and second intermediate containers according to the treatment time, where time (in seconds) is represented along the X or horizontal axis and weight (in grams) is represented along the Y or vertical axis.
- the control unit primes the source flow controller 33, opens the container selection controller 32, and does not operate the output controller 31 such that no treatment solution is removed from fluid line 157 by the fluid output controller 31.
- the source flow controller 33 controls the flow of treatment solution into the fluid line 157 from the treatment solution source 60.
- the second intermediate container 12 is downstream from the source flow controller 33 in relation to the first intermediate container 11, but is located at a position that is lower than the first intermediate container 11. Because it is lower than the first intermediate container 11, the second intermediate container 12 is loaded with treatment solution before the first intermediate container 11. Thus, it may be seen that the weight of the second intermediate container 12 (PE2 on FIG. 11 ) increases regularly in priority relative to the weight of the first intermediate container 11 (PE1 on FIG. 11 ), which remains unchanged.
- the blood treatment apparatus 1 will operate according to a first phase as depicted in FIG. 9 :
- the source flow controller 33 continues to deliver treatment solution, the container selection controller 32 is closed, and the output controller 31 can be operated to deliver treatment solution to the port 10.
- the second intermediate container 12 will unload into the fluid line 157 where the treatment solution will be delivered to the output controller 31 for, e.g., the start of a therapy session. It may be seen that the weight of the second intermediate container 12 regularly decreases (e.g., from approximately 280 g to approximately 120 g).
- the first intermediate container 11 is loaded with the treatment solution coming from the source flow controller 33.
- a weight increase of the first intermediate container 11, e.g., from 80 g to approximately 680 g, can be seen.
- This first phase is performed until a minimum weight threshold of the second intermediate container 12 (e.g., approx.. 120 g in the depicted embodiment) is reached, or a maximum weight threshold of the first intermediate container (e.g., 680 g in the depicted embodiment) is reached, or the first of the two above-mentioned thresholds is reached.
- a minimum weight threshold of the second intermediate container 12 e.g., approx.. 120 g in the depicted embodiment
- a maximum weight threshold of the first intermediate container e.g., 680 g in the depicted embodiment
- control unit controls the entry into the second phase, which is depicted in FIG. 10 .
- treatment solution flows out of the first intermediate container 11 (as indicated by the decline in weight of the first intermediate container 11) while treatment solution flows into the second intermediate container 12 (as indicated by the increase in weight of the second intermediate container 12).
- the control unit 41 opens the container selection controller 32 and stops the flow of treatment solution from the source flow controller 33 (in some embodiments, the source flow controller 33 is stopped before the container selection controller 32 is opened).
- treatment solution from the first intermediate container 11 flows into the second intermediate container 12 and to the output controller 31.
- first intermediate container 11 reaches a selected minimum weight (e.g., approx.. 100 g in the depicted embodiment) or the second intermediate container 12 reaches a selected maximum weight (e.g., approx. 590 g in the depicted embodiment).
- a selected minimum weight e.g., approx.. 100 g in the depicted embodiment
- a selected maximum weight e.g., approx. 590 g in the depicted embodiment
- the system switches back to the first phase in which the source flow controller 33 delivers treatment solution and the container selection controller 32 is closed while the output controller 31 delivers treatment solution to the port 10.
- the second intermediate container 12 With the container selection controller 32 closed, the second intermediate container 12 unloads treatment solution that is delivered to the output controller 31 to continue the therapy session. It may be seen that the weight of the second intermediate container 12 regularly decreases (e.g., from approximately 590 g to approximately 120 g).
- the first intermediate container 11 is loaded with the treatment solution coming from the source flow controller 33.
- the first intermediate container 11 reaches its selected maximum threshold (e.g., approx. 680 g) before the second container 12 reaches its selected minimum threshold.
- delivery of treatment solution into the first intermediate container 11 is halted as indicated by the steady-state (constant) weight of the first intermediate container in FIG. 11 .
- the switch back to second phase operation could be triggered at any time after the first intermediate container 11 reaches its selected maximum threshold (which would occur before the second intermediate container reaches its selected minimum threshold, e.g., at about 400 g or less in the embodiment depicted in FIG. 11 ).
- the system can then enter the second phase operation as described herein, with switches between the first and second phases being based on the minimum and maximum thresholds for the first and second intermediate containers 11 and 12 until the end of a therapy session is reached.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001975.7A EP2641624B1 (de) | 2012-03-21 | 2012-03-21 | Lieferung einer Behandlungslösung in eine extrakorporale Blutbehandlungsvorrichtung |
ES12001975T ES2570804T3 (es) | 2012-03-21 | 2012-03-21 | Suministro de solución de tratamiento en un aparato de tratamiento extracorpóreo de sangre |
CA2865542A CA2865542C (en) | 2012-03-21 | 2013-03-20 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
AU2013202696A AU2013202696B2 (en) | 2012-03-21 | 2013-03-20 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
KR1020147029320A KR102105431B1 (ko) | 2012-03-21 | 2013-03-20 | 체외 혈액 처리 장치에서의 처리액 운반 |
PCT/IB2013/052202 WO2013140346A1 (en) | 2012-03-21 | 2013-03-20 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
US14/386,062 US9931452B2 (en) | 2012-03-21 | 2013-03-20 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
CN201380015201.2A CN104203305B (zh) | 2012-03-21 | 2013-03-20 | 体外血液治疗设备中的治疗溶液输送 |
IN7776DEN2014 IN2014DN07776A (de) | 2012-03-21 | 2014-09-17 | |
US15/913,231 US11020517B2 (en) | 2012-03-21 | 2018-03-06 | Treatment solution delivery in an extracorporeal blood treatment apparatus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001975.7A EP2641624B1 (de) | 2012-03-21 | 2012-03-21 | Lieferung einer Behandlungslösung in eine extrakorporale Blutbehandlungsvorrichtung |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2641624A1 true EP2641624A1 (de) | 2013-09-25 |
EP2641624B1 EP2641624B1 (de) | 2016-03-02 |
Family
ID=45991996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12001975.7A Active EP2641624B1 (de) | 2012-03-21 | 2012-03-21 | Lieferung einer Behandlungslösung in eine extrakorporale Blutbehandlungsvorrichtung |
Country Status (8)
Country | Link |
---|---|
US (2) | US9931452B2 (de) |
EP (1) | EP2641624B1 (de) |
KR (1) | KR102105431B1 (de) |
AU (1) | AU2013202696B2 (de) |
CA (1) | CA2865542C (de) |
ES (1) | ES2570804T3 (de) |
IN (1) | IN2014DN07776A (de) |
WO (1) | WO2013140346A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2016104720A1 (ja) * | 2014-12-25 | 2017-10-19 | アサヒカセイメディカルヨーロッパゲーエムベーハー | 血液処理システム |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9399091B2 (en) | 2009-09-30 | 2016-07-26 | Medtronic, Inc. | System and method to regulate ultrafiltration |
US9192707B2 (en) | 2011-04-29 | 2015-11-24 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
ES2647775T3 (es) | 2011-08-02 | 2017-12-26 | Medtronic, Inc. | Sistema de hemodiálisis que tiene una trayectoria de flujo con un volumen distensible controlado |
EP2744537B1 (de) | 2011-08-16 | 2018-01-24 | Medtronic, Inc. | Modulares hämodialysesystem |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10543052B2 (en) | 2013-02-01 | 2020-01-28 | Medtronic, Inc. | Portable dialysis cabinet |
US9623164B2 (en) | 2013-02-01 | 2017-04-18 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
EP2968720B1 (de) * | 2013-03-15 | 2017-04-19 | Gambro Lundia AB | Extrakorporale blutbehandlungsvorrichtung mit reservoirstatusleuchten |
CN105848581B (zh) | 2013-11-04 | 2019-01-01 | 美敦力公司 | 用于管理身体中的体液体积的方法和装置 |
US9895479B2 (en) | 2014-12-10 | 2018-02-20 | Medtronic, Inc. | Water management system for use in dialysis |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US10874790B2 (en) | 2016-08-10 | 2020-12-29 | Medtronic, Inc. | Peritoneal dialysis intracycle osmotic agent adjustment |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11305048B2 (en) * | 2016-10-19 | 2022-04-19 | Medtec Medical, Inc. | Electronic vacuum regulator device |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
JP7262207B2 (ja) * | 2018-11-08 | 2023-04-21 | 日機装株式会社 | 血液浄化装置 |
US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US10879151B2 (en) * | 2018-12-28 | 2020-12-29 | Texas Instruments Incorporated | Semiconductor package with liquid metal conductors |
US11517653B2 (en) | 2019-11-05 | 2022-12-06 | Diality Inc. | Hemodialysis system reservoir level sensor |
CA3175888A1 (en) * | 2020-03-19 | 2021-09-23 | Carefusion 303, Inc. | Iv workflow management system |
CN117813122A (zh) * | 2021-08-09 | 2024-04-02 | 甘布罗伦迪亚股份公司 | 用于供应用于肾脏替代治疗的医用流体的系统和操作这种系统的方法 |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11965763B2 (en) | 2021-11-12 | 2024-04-23 | Mozarc Medical Us Llc | Determining fluid flow across rotary pump |
US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
WO2023110977A2 (en) * | 2021-12-15 | 2023-06-22 | Baxter International Inc. | Weight-based systems for use in extracorporeal blood treatment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040267183A1 (en) * | 2003-06-25 | 2004-12-30 | Hospal International Marketing Management Snc. | Extracorporeal treatment device with automatic emptying of waste bag |
EP1543853A1 (de) * | 2002-08-08 | 2005-06-22 | Asahi Kasei Medical Co., Ltd. | Blutreinigungsvorrichtung und bedienungsverfahren dafür |
EP2019296A1 (de) * | 2006-04-14 | 2009-01-28 | Jms Co., Ltd. | Gewichtssensor und balancesteuerung |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR765258A (fr) | 1933-12-07 | 1934-06-05 | Installation de jaugeage automatique des liquides | |
GB1440185A (en) | 1972-07-14 | 1976-06-23 | Smiths Industries Ltd | Medico-surgical liquid-measuring apparatus |
JPS5383397A (en) | 1976-12-28 | 1978-07-22 | Nikkiso Co Ltd | Method and device for measuring quantity of extra filtration through artificial dialyzer |
DE2734561A1 (de) | 1977-07-30 | 1979-02-08 | Fresenius Chem Pharm Ind | Vorrichtung zur ultrafiltrationssteuerung bei der haemodialyse |
WO1981000518A1 (en) | 1979-08-21 | 1981-03-05 | Vsesoyuzny Nii Med Priborostro | Artificial kidney apparatus |
JPS56132961A (en) | 1980-03-22 | 1981-10-17 | Daicel Ltd | Artificial kidney device |
DE3213390A1 (de) | 1982-04-10 | 1983-10-20 | Dieter 3000 Hannover Biela | Vorrichtung zur bilanzierung des fluessigkeitsaustausches bei haemofiltrationen |
JPS5937959A (ja) | 1982-08-28 | 1984-03-01 | 財団法人鷹揚郷 | 限外「ろ」過量測定装置 |
DE3302804C2 (de) | 1983-01-28 | 1985-03-14 | Fresenius AG, 6380 Bad Homburg | Vorrichtung zur Entfernung von Wasser aus Blut |
IT8504923V0 (it) | 1985-06-07 | 1985-06-07 | Miren Srl | Dispositivo per il controllo del bilancio idrico di un paziente durante il trattamento di emodialisi |
IT206453Z2 (it) | 1985-08-09 | 1987-08-10 | Hospal Dasco Spa | Dispositivo di misura della quantita di ultrafiltrato asportata durante un trattamento di dialisi |
FR2594340A1 (fr) | 1986-02-14 | 1987-08-21 | Pf Medicament | Dispositif perfectionne de dialyse |
DE3801316A1 (de) | 1987-01-20 | 1988-07-28 | Knoll Ag | Geraet zur behandlung uraemischer patienten |
US4994026A (en) | 1988-08-31 | 1991-02-19 | W. R. Grace & Co.-Conn. | Gravity flow fluid balance system |
FR2647679B1 (fr) | 1989-06-02 | 1991-08-23 | Hospal Ind | Dispositif et procede de mesure de l'ultrafiltration dans un rein artificiel |
FR2680975B1 (fr) | 1991-09-10 | 1998-12-31 | Hospal Ind | Rein artificiel muni de moyens pour doser une substance dans le sang. |
US5672481A (en) | 1991-10-23 | 1997-09-30 | Cellpro, Incorporated | Apparatus and method for particle separation in a closed field |
US5441636A (en) | 1993-02-12 | 1995-08-15 | Cobe Laboratories, Inc. | Integrated blood treatment fluid module |
DE9403081U1 (de) | 1994-02-24 | 1994-04-21 | Vogel, Karl, 90768 Fürth | Gerät zur Ermittlung von Substituat- und Filtratmengen |
FR2723002B1 (fr) | 1994-07-26 | 1996-09-06 | Hospal Ind | Dispositif et procede pour preparer un liquide de traitement par filtration |
EP0722744A1 (de) | 1995-01-19 | 1996-07-24 | Ube Industries, Ltd. | Gerät zur kontinuierlichen Reinigung von Blut |
US5650071A (en) | 1995-06-07 | 1997-07-22 | Cobe Laboratories, Inc. | Technique for priming and recirculating fluid through a dialysis machine to prepare the machine for use |
IT1285623B1 (it) | 1996-03-18 | 1998-06-18 | Bellco Spa | Apparecchiatura per trattamenti di dialisi |
US6852090B2 (en) * | 1997-02-14 | 2005-02-08 | Nxstage Medical, Inc. | Fluid processing systems and methods using extracorporeal fluid flow panels oriented within a cartridge |
DE19708391C1 (de) | 1997-03-01 | 1998-10-22 | Fresenius Medical Care De Gmbh | Verfahren und Vorrichtung zur Ultrafiltration bei der Hämodialyse |
US5980478A (en) | 1997-10-10 | 1999-11-09 | Transvivo, Inc. | Apparatus and method for the treatment of acute and chronic renal disease by continuous passive plasma ultrafiltration |
US5993657A (en) | 1998-02-03 | 1999-11-30 | Williams; Edward L. | Adjustable collection canister for continuous renal replacement therapy |
US6561996B1 (en) | 1998-05-19 | 2003-05-13 | Transvivo, Inc. | Apparatus and method for in vivo hemodialysis |
EP1165148A1 (de) | 1999-03-30 | 2002-01-02 | Gambro Lundia AB | Verfahren und vorrichtung zur sterilisation eines hitzeempfindlichen fluids |
CA2369576C (en) | 1999-04-23 | 2005-07-05 | William Frederick Weitzel | Extracorporeal circuit and related methods |
US7153286B2 (en) | 2002-05-24 | 2006-12-26 | Baxter International Inc. | Automated dialysis system |
US7351218B2 (en) * | 2002-12-20 | 2008-04-01 | Gambro Lundia Ab | Device and process for extracorporeal treatment by citrate anticoagulant |
EP1592494B1 (de) * | 2003-01-07 | 2009-06-24 | NxStage Medical, Inc. | Chargenfiltriersystem zur herstellung einer sterilen ersatzflüssigkeit für nierenbehandlungen |
US7247146B2 (en) | 2003-02-07 | 2007-07-24 | Gambro Lundia Ab | Support element for an integrated blood treatment module, integrated blood treatment module and extracorporeal blood treatment apparatus equipped with said integrated module |
-
2012
- 2012-03-21 EP EP12001975.7A patent/EP2641624B1/de active Active
- 2012-03-21 ES ES12001975T patent/ES2570804T3/es active Active
-
2013
- 2013-03-20 WO PCT/IB2013/052202 patent/WO2013140346A1/en active Application Filing
- 2013-03-20 CA CA2865542A patent/CA2865542C/en active Active
- 2013-03-20 AU AU2013202696A patent/AU2013202696B2/en active Active
- 2013-03-20 US US14/386,062 patent/US9931452B2/en active Active
- 2013-03-20 KR KR1020147029320A patent/KR102105431B1/ko active IP Right Grant
-
2014
- 2014-09-17 IN IN7776DEN2014 patent/IN2014DN07776A/en unknown
-
2018
- 2018-03-06 US US15/913,231 patent/US11020517B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1543853A1 (de) * | 2002-08-08 | 2005-06-22 | Asahi Kasei Medical Co., Ltd. | Blutreinigungsvorrichtung und bedienungsverfahren dafür |
US20040267183A1 (en) * | 2003-06-25 | 2004-12-30 | Hospal International Marketing Management Snc. | Extracorporeal treatment device with automatic emptying of waste bag |
EP2019296A1 (de) * | 2006-04-14 | 2009-01-28 | Jms Co., Ltd. | Gewichtssensor und balancesteuerung |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2016104720A1 (ja) * | 2014-12-25 | 2017-10-19 | アサヒカセイメディカルヨーロッパゲーエムベーハー | 血液処理システム |
EP3238761A4 (de) * | 2014-12-25 | 2018-06-06 | Asahi Kasei Medical Europe GmbH | Blutbehandlungssystem |
JP2019115694A (ja) * | 2014-12-25 | 2019-07-18 | 旭化成メディカル株式会社 | 血液処理システム |
Also Published As
Publication number | Publication date |
---|---|
EP2641624B1 (de) | 2016-03-02 |
CN104203305A (zh) | 2014-12-10 |
WO2013140346A1 (en) | 2013-09-26 |
IN2014DN07776A (de) | 2015-05-15 |
AU2013202696A1 (en) | 2013-10-10 |
US9931452B2 (en) | 2018-04-03 |
US20180193544A1 (en) | 2018-07-12 |
KR102105431B1 (ko) | 2020-04-29 |
US11020517B2 (en) | 2021-06-01 |
CA2865542A1 (en) | 2013-09-26 |
US20150034538A1 (en) | 2015-02-05 |
ES2570804T3 (es) | 2016-05-20 |
KR20140137443A (ko) | 2014-12-02 |
AU2013202696B2 (en) | 2015-03-19 |
CA2865542C (en) | 2019-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11020517B2 (en) | Treatment solution delivery in an extracorporeal blood treatment apparatus | |
JP6936267B2 (ja) | 高対流家庭用血液透析/血液濾過および吸着剤システム | |
EP2883566A1 (de) | Extrakorporales Blutbehandlungssystem und Ventileinheit für Prädilution und Postdilution | |
US10328193B2 (en) | Extracorporeal blood treatment apparatus with multiple treatment solution reservoirs | |
JP5822319B1 (ja) | 持続的血液浄化用装置 | |
JP4757168B2 (ja) | 血液透析装置における逆濾過透析液の送液方法および血液透析装置 | |
CN112312938B (zh) | 透析期间的耗尽时间的计算 | |
AU2018397260B2 (en) | Apparatus for extracorporeal blood treatment | |
JP6022846B2 (ja) | 血液浄化装置及び血液浄化システム | |
CN113038979A (zh) | 血液净化装置 | |
US20110036768A1 (en) | Continuous blood purification system provided with syringe pumps | |
CN108712917B (zh) | 用于体外的血液治疗的设备和运行用于体外的血液治疗的设备的方法 | |
JP2010528732A (ja) | 単針動作での血液処理装置および方法 | |
CN111936179B (zh) | 血液管组、开环或闭环控制装置、血液治疗设备和用于单针治疗的方法 | |
US10780211B2 (en) | Apparatus for carrying out an apheresis treatment | |
EP2641625B1 (de) | Vorrichtung zur extrakorporalen Behandlung von Blut mit mehreren Behältern für Behandlungslösung | |
CN112135646A (zh) | 用于补偿由于机器停机时间而未被引出的流体体积的患者流体引出速率的计算 | |
JP2019508129A (ja) | 体外血液処理を実行する装置 | |
CN104203305B (zh) | 体外血液治疗设备中的治疗溶液输送 | |
JP7224219B2 (ja) | 血液浄化装置 | |
EP3603695B1 (de) | Blutreinigungsvorrichtung und priming-verfahren dafür | |
CN117120117A (zh) | 正向渗透单元的灌注 | |
JP2020151034A (ja) | 透析装置及び回路セットの判定方法 | |
Circuit | Single-Patient Hemodialysis Machines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
17P | Request for examination filed |
Effective date: 20131009 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150702 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150907 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 777548 Country of ref document: AT Kind code of ref document: T Effective date: 20160315 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012015082 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2570804 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160520 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160302 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 777548 Country of ref document: AT Kind code of ref document: T Effective date: 20160302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160603 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160702 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160704 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012015082 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160321 |
|
26N | No opposition filed |
Effective date: 20161205 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160602 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120321 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160321 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160331 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160302 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240220 Year of fee payment: 13 Ref country code: GB Payment date: 20240220 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240220 Year of fee payment: 13 Ref country code: FR Payment date: 20240220 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240402 Year of fee payment: 13 |